60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease

Key Takeaways Explain This Topic AI

Major Neurocognitive Disorder (Dementia) requires significant cognitive decline across >=1 cognitive domains (complex attention, executive function, learning/memory, language, perceptual-motor, social cognition) that impairs functional independence in everyday activities (IADLs/ADLs); Mild Cognitive Impairment (MCI) involves objective cognitive decline with preserved independent functioning.

The Montreal Cognitive Assessment (MoCA, cutoff <26/30) has superior sensitivity for MCI, vascular dementia, and executive dysfunction compared to the Mini-Mental State Examination (MMSE); the Mini-Cog (clock drawing + 3-word recall) provides a validated, rapid 3-minute clinic screen.

Mandatory reversible etiology laboratory evaluation includes serum TSH, Vitamin B12 (supplemented by methylmalonic acid if borderline 200-400 pg/mL), CBC, and CMP; structural neuroimaging (non-contrast Head CT or Brain MRI) is required to rule out normal pressure hydrocephalus (NPH: triad of urinary incontinence, cognitive decline, and magnetic gait ataxia with ventriculomegaly out of proportion to sulcal atrophy), subdural hematoma, neoplasm, and stroke.

Primary dementia subtypes exhibit distinct clinicopathological profiles: Alzheimer disease (60-70%) presents with early episodic declarative memory loss and hippocampal atrophy due to amyloid-beta plaques and tau tangles; Vascular dementia features stepwise executive dysfunction and leukoaraiosis; Frontotemporal dementia (FTD / Pick disease) presents at younger ages (45-65y) with profound personality changes, disinhibition, hyperorality, or primary progressive aphasia.

Dementia with Lewy Bodies (DLB) is defined by alpha-synuclein inclusions, fluctuating cognition/alertness, recurrent detailed visual hallucinations, REM sleep behavior disorder, and parkinsonism developing within 1 year of cognitive decline; first-generation and typical antipsychotics carry an EXTREME PRESCRIBING WARNING due to catastrophic neuroleptic hypersensitivity (severe rigidity, delirium, neuroleptic malignant syndrome, coma, death); if psychosis treatment is unavoidable, lowest-dose quetiapine or pimavanserin must be used.

Last updated: September 2026

Diagnostic Framework: Major Neurocognitive Disorder vs. Mild Cognitive Impairment

Cognitive impairment in older adults represents one of the most common and challenging clinical scenarios encountered in family medicine. The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) categorizes progressive cognitive decline under the umbrella of Neurocognitive Disorders (NCD) , establishing clear operational distinctions between normal age-related cognitive decline, Mild Neurocognitive Disorder (Mild Cognitive Impairment [MCI]), and Major Neurocognitive Disorder (Dementia). DSM-5 NEUROCOGNITIVE DISORDER CRITERIA

Diagnostic Category Cognitive Assessment Findings Impact on Daily Function (IADLs/ADLs)
═════════════════════════════════════════════════════════════════════════════════════════════════════════════
Age-Associated Subjective complaints; objective testing Preserved; independent in all activities;

Cognitive Decline within 1 standard deviation of age-matched no compensatory strategies needed.

norms; preserved processing.

─────────────────────────────────────────────────────────────────────────────────────────────────────────
Mild Neurocognitive Objective impairment (1.0 to 2.0 standard INDEPENDENCE PRESERVED; complex IADLs
Disorder (MCI) deviations below norm) in >= 1 cognitive maintained, though may require greater effort,

domain on formal testing. compensatory strategies, or accommodation.

─────────────────────────────────────────────────────────────────────────────────────────────────────────
Major Neurocognitive Significant cognitive decline (> 2.0 LOSS OF INDEPENDENCE; cognitive deficits
Disorder (Dementia) standard deviations below norm) in >= 1 interfere directly with independence in

cognitive domain. everyday activities (requires assistance with IADLs/ADLs).

═════════════════════════════════════════════════════════════════════════════════════════════════════════════
The Six Core Cognitive Domains

Accurate syndromic characterization requires evaluating performance across the six neurocognitive domains delineated by the DSM-5:

Complex Attention : Sustained attention, divided attention, selective attention, and processing speed. Manifests clinically as difficulty with multi-step tasks, easy distractibility, or inability to perform mental calculations.

Executive Function : Planning, decision-making, working memory, cognitive flexibility, abstract reasoning, and overriding habitual responses. Manifests as inability to manage complex finances, difficulty planning a meal, or struggling to adapt to schedule changes.

Learning and Memory : Immediate memory, recent/episodic declarative memory (free recall, cued recall, recognition memory), and long-term semantic memory. Manifests as repeating questions within minutes, losing track of personal possessions, or forgetting recent family events.

Language : Expressive language (naming, word finding, fluency, grammar) and receptive language (comprehension). Manifests as word-finding pauses ("tip-of-the-tongue"), circumlocution, paraphasic errors, or difficulty comprehending multi-clause sentences.

Perceptual-Motor : Visuoconstructional ability, visual perception, praxis (performing purposeful learned movements), and gnosis (recognizing objects or faces). Manifests as getting lost in familiar neighborhoods, inability to use common household tools (apraxia), or failing to recognize familiar faces (prosopagnosia).

Social Cognition : Recognition of emotions, theory of mind (empathy), and behavioral regulation in social contexts. Manifests as social disinhibition, inappropriate remarks, apathy, insensitivity to social cues, or dramatic loss of empathy.

Functional Assessment: IADLs vs. ADLs

The pivotal boundary separating MCI from dementia is the preservation of functional independence :

Instrumental Activities of Daily Living (IADLs) : Complex multi-step activities required to live independently in the community. These are impaired early in dementia: managing medications, handling finances and bills, driving, navigating public transit, meal preparation, shopping, housekeeping, and telephone use.

Basic Activities of Daily Living (ADLs) : Fundamental self-care tasks that are typically preserved until intermediate-to-advanced stages: bathing, dressing, toileting, transferring/ambulation, continence, and feeding.

Formal Cognitive Screening & Reversible Etiology Workup

Every patient presenting with cognitive concerns requires a structured, multi-modal clinical evaluation to establish objective deficits and systematically rule out potentially reversible or treatable secondary causes. COMPARATIVE ANALYSIS OF COGNITIVE SCREENING TOOLS

Screening Tool Scale Threshold Administration Time Strengths & High-Yield ABFM Pearls
═════════════════════════════════════════════════════════════════════════════════════════════════════════════

Montreal Cognitive 0-30 < 26 / 30 10 - 12 minutes • HIGH SENSITIVITY (90%) for MCI and early dementia.

Assessment (MoCA) • Rigorous testing of executive function (trail making,

phonemic fluency) and visuospatial processing.

• Superior tool for Vascular Dementia and Parkinson's.

• Add +1 point for individuals with <= 12 years education.

─────────────────────────────────────────────────────────────────────────────────────────────────────────

Mini-Mental State 0-30 < 24 / 30 8 - 10 minutes • Heavily weighted toward language and orientation.

Examination (MMSE) • POOR SENSITIVITY for MCI and executive dysfunction.

• High false-negative rate in highly educated individuals.

• Significant ceiling effect; proprietary copyright fees.

─────────────────────────────────────────────────────────────────────────────────────────────────────────
Mini-Cog 0-5 < 3 / 5 3 - 5 minutes • Combines 3-word recall (0-3 points) with an unprompted

indicates clock drawing test (CDT; 0 or 2 points).

impairment • Abnormal clock (wrong numbers/hands) = immediate 0 pts.

• Rapid, highly specific, language/education resilient.

═════════════════════════════════════════════════════════════════════════════════════════════════════════════
Laboratory Screening for Reversible Causes

Although truly reversible dementias account for <5% of cases, identifying and treating secondary metabolic or endocrine derangements can substantially improve baseline cognition and slow functional decline. The American Academy of Neurology (AAN) and American College of Physicians (ACP) mandate:

Serum Thyroid-Stimulating Hormone (TSH) : Exclude overt or severe subclinical hypothyroidism (elevated TSH, depressed free T4), which causes psychomotor slowing, apathy, depression, and reversible executive dysfunction.

Serum Vitamin B12 (Cobalamin) : Deficiency causes subacute combined degeneration of the spinal cord (posterior and lateral column loss) and megaloblastic madness (neuropsychiatric disturbance, sensory ataxia, memory loss).

Clinical Pearl : If serum B12 is borderline (200-400 pg/mL), reflexively check serum methylmalonic acid (MMA) and homocysteine . Elevated MMA confirms true cellular cobalamin deficiency even with a normal peripheral blood count.

Comprehensive Metabolic Panel (CMP) : Evaluates serum sodium (hyponatremia causing lethargy/confusion), serum calcium (hypercalcemia causing delirium and encephalopathy), blood urea nitrogen and creatinine (uremia), and hepatic function tests (hepatic encephalopathy).

Complete Blood Count (CBC) : Identifies occult anemia, leukopenia, or infectious processes.

Selective Diagnostic Testing : Indicated based on individual clinical risk factors:

Rapid Plasma Reagin (RPR) or VDRL : Screen for neurosyphilis in patients with Argyll Robertson pupils, tabetic gait, or unexplained behavioral changes.

HIV 1/2 Antigen/Antibody : Recommended in high-risk individuals or patients presenting with rapid subcortical cognitive decline under 60 years of age.

Serum Folate : Checked concurrently with B12 in malnourished or alcohol-dependent individuals.

Urine Toxicology Screen & Medication Reconciliation : Review for anticholinergic burden (diphenhydramine, tricyclic antidepressants, oxybutynin), benzodiazepines, and sedative-hypnotics.

Structural Neuroimaging: Head CT vs. Brain MRI

Guidelines mandate baseline structural neuroimaging with non-contrast Head CT or Brain MRI (without IV contrast) for any newly suspected cognitive impairment to exclude structural lesions:

Chronic Subdural Hematoma (SDH) : Bridging cortical vein tears in elderly individuals with cerebral atrophy; can present with insidious fluctuating confusion following minor forgotten trauma.

Intracranial Neoplasms : Primary brain tumors (e.g., glioblastoma, frontal meningioma) or metastatic lesions.

Cerebrovascular Disease : Silent cortical or subcortical lacunar infarctions, territorial infarcts, or strategic thalamic strokes.

Normal Pressure Hydrocephalus (NPH) : A treatable communicating hydrocephalus characterized by the pathognomonic clinical triad:

"Wet" : Urinary urgency progressing to urge incontinence due to loss of frontal cortical inhibition of the detrusor.

"Wacky" : Subcortical cognitive impairment, apathy, psychomotor slowing, and impaired attention.

"Wobbly" : Prominent magnetic, apraxic, broad-based, shuffling gait (feet appear "glued to the floor", short stride length, en bloc turning, preserved arm swing).

Neuroimaging Hallmark : Markedly enlarged lateral and third ventricles out of proportion to cortical sulcal enlargement ( Evans Index > 0.30 , defined as the maximal width of the frontal horns divided by the maximal internal diameter of the skull).

Diagnostic & Therapeutic Intervention : High-volume lumbar puncture (Fisher tap test) removing 30 to 50 mL of CSF; documentation of significant objective gait improvement (speed, stride length) 30-60 minutes post-tap confirms diagnosis and predicts excellent long-term response to ventriculoperitoneal (VP) shunting .

Important

THE NPH GAIT HALLMARK In Normal Pressure Hydrocephalus, the gait disturbance is almost invariably the earliest, most prominent, and most shunt-responsive symptom . Dementia presenting prior to gait difficulty or urinary incontinence strongly argues against NPH and points to Alzheimer disease or Lewy body dementia with secondary ex vacuo ventriculomegaly (ventricular enlargement purely secondary to underlying parenchymal atrophy).

Differential Diagnosis of Primary Dementia Syndromes

The vast majority of progressive neurocognitive disorders represent primary neurodegenerative or cerebrovascular conditions. Differentiating these syndromes is critical for disease-specific management, prognostic counseling, and the avoidance of fatal pharmacotherapy errors. PRIMARY DEMENTIA SYNDROMES: CLINICAL & PATHOLOGICAL COMPARISON

Feature Alzheimer Disease (AD) Vascular Dementia (VaD) Dementia with Lewy Bodies (DLB) Frontotemporal Dementia (FTD)

═════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════

Epidemiology Most common (60% - 70%) Second most common (15% - 20%) Third most common (10% - 15%) Onset younger (45 - 65y);

Prevalence doubles q5y >65y Associated with HTN, DM, CAD Male predominance Strong genetic link (~40%)

─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

Neuropathology Extracellular Amyloid-Beta Subcortical arteriolosclerosis Intracellular Lewy bodies Frontotemporal lobar

(Aβ42) neuritic plaques; lacunar infarcts; ischemic (alpha-synuclein inclusions) degeneration (tau inclusions
hyperphosphorylated tau demyelination of white matter in basal ganglia, limbic, and or TDP-43 inclusions)
neurofibrillary tangles (leukoaraiosis) cortical neurons

Clinical Course Insidious onset, gradual Stepwise deterioration or Fluctuating alertness and Insidious onset, rapid progression;

relentless linear decline fluctuating decline tied to attention; episodic delirium-like early personality/behavioral

cerebrovascular events lucid vs confused intervals change; memory preserved early

Signature Early episodic declarative Early executive dysfunction, 1) Fluctuating cognition 1) Behavioral: disinhibition,

Features memory loss, impaired psychomotor slowing, apathy, 2) Detailed visual hallucinations apathy, hyperorality, loss of empathy

delayed free recall, word- focal motor/sensory deficits, 3) REM Sleep Behavior Disorder 2) Language: primary progressive

finding pauses, disorientation pseudobulbar affect 4) Spontaneous parkinsonism aphasia (PPA)

Neuroimaging Medial temporal lobe and Multiple lacunar infarcts, Generalized cortical atrophy; Circumscribed frontal and/or

bilateral hippocampal extensive confluent periven- preservation of medial temporal anterior temporal lobar atrophy

atrophy on coronal T1 MRI tricular white matter disease lobes on structural MRI ("knife-edge" gyral atrophy)

Pharmacotherapy ChEIs (Donepezil, Intensive vascular risk-factor Cholinesterase inhibitors; SSRIs/trazodone for agitation;

Rivastigmine), Memantine, modification (statin, BP, DO NOT USE TYPICAL CHOLINESTERASE INHIBITORS

anti-amyloid monoclonal Abs antiplatelet); symptomatic ChEIs ANTIPSYCHOTICS (Lethal!) ARE INEFFECTIVE/WORSEN BEHAVIOR

1. Alzheimer Disease (AD)

Alzheimer disease represents 60% to 70% of all dementias. The neuropathological hallmarks consist of:

Amyloid-Beta 42 (Aβ42) Plaques : Extracellular senile plaques composed of insoluble cleaved amyloid precursor protein fragments.

Neurofibrillary Tangles (NFTs) : Intracellular aggregates of hyperphosphorylated tau protein, a microtubule-stabilizing protein. Tau density correlates closely with clinical cognitive decline.

Clinical Progression : Onset is insidious. The earliest and most prominent deficit is the loss of recent episodic declarative memory (rapid forgetting of recently acquired information, failure to retain delayed recall lists even with cueing), due to initial synaptic destruction in the entorhinal cortex and hippocampi. Remote autobiographical memory and procedural memory remain intact until late stages. As pathology spreads across the association cortices, patients develop anomic aphasia, visuospatial disorientation, executive impairment, and apraxia.

Neuroimaging : High-resolution coronal T1-weighted Brain MRI demonstrates symmetrical or asymmetrical atrophy of the hippocampi, parahippocampal gyri, and medial temporal lobes , accompanied by compensatory enlargement of the temporal horns.

2. Vascular Dementia (VaD)

Vascular dementia (Vascular Neurocognitive Disorder) arises from ischemic or hemorrhagic brain injury:

Mechanisms : Large-vessel territorial strokes, multiple small-vessel subcortical lacunar infarctions, or extensive chronic microvascular ischemia causing demyelination of periventricular white matter (Binswanger disease / arteriolosclerotic leukoaraiosis).

Clinical Profile : The classic trajectory is a stepwise or abrupt decline , where each drop in functional status corresponds to a discrete clinical or subclinical cerebrovascular event. Unlike Alzheimer disease, memory impairment is not necessarily the presenting feature. Instead, patients exhibit early, profound executive dysfunction (inability to sequence, organize, or plan), marked psychomotor slowing, apathy, emotional lability ( pseudobulbar affect ), and focal neurological signs (unilateral hyperreflexia, asymmetric pronator drift, Babinski sign).

Management : Aggressive secondary cardiovascular risk reduction—intensive blood pressure control (<130/80 mmHg), high-intensity statin therapy, antiplatelet therapy (aspirin or clopidogrel), and glycemic control. Cholinesterase inhibitors offer modest symptomatic benefit for concurrent subcortical cholinergic deafferentation.

Dementia with Lewy Bodies & Antipsychotic Hypersensitivity

Dementia with Lewy Bodies (DLB) is the third most common cause of neurodegenerative dementia. Pathologically, it is characterized by the widespread cortical, limbic, and brainstem accumulation of alpha-synuclein cytoplasmic inclusions (Lewy bodies) .

Core Clinical Criteria

Under the 2017 DLB Consortium diagnostic criteria, a diagnosis of probable DLB requires dementia plus at least two of the following four core clinical features (or one core feature plus one indicative biomarker):

Fluctuating Cognition with Pronounced Variations in Attention and Alertness : Patients experience unpredictable, episodic oscillations between lucid coherence and profound confusion, unresponsiveness, or excessive daytime somnolence (staring off into space for long intervals).

Recurrent, Well-Formed, Detailed Visual Hallucinations : Present in up to 80% of patients. Hallucinations are characteristically vivid, realistic, and animate (e.g., fully formed children, small animals, deceased relatives, or figures standing silently in the room). They are often emotionally neutral or curious, rather than threatening early in the disease.

REM Sleep Behavior Disorder (RBD) : Loss of the normal muscle atonia that accompanies rapid eye movement (REM) sleep. Patients physically act out their dreams (thrashing, punching, kicking, yelling, or leaping from bed), frequently causing physical injury to themselves or their bed partners. RBD often precedes the onset of cognitive or motor signs by 5 to 20 years.

Spontaneous Motor Parkinsonism : Bradykinesia, resting tremor, cogwheel rigidity, and postural instability. Unlike idiopathic Parkinson disease, the parkinsonism in DLB is typically symmetrical at onset, has less prominent resting tremor, and features more pronounced early gait instability.

The "One-Year Rule"

The chronological relationship between cognitive decline and motor parkinsonism distinguishes DLB from Parkinson's Disease Dementia (PDD):

Dementia with Lewy Bodies (DLB) : Cognitive impairment precedes, develops concurrently with, or appears within 12 months of the onset of motor parkinsonian symptoms.

Parkinson's Disease Dementia (PDD) : Motor Parkinson's disease is well-established for greater than 1 year (typically many years) before the emergence of significant dementia. THE "1-YEAR RULE" IN ALPHA-SYNUCLEINOPATHIES

Onset of Parkinsonism 1 Year Mark Clinical Diagnosis
─────────────────────────────────────────────────────────────────────────────────────────────
Dementia occurs BEFORE or WITHIN 1 year of motor parkinsonism ---------> Dementia with Lewy Bodies (DLB)

Motor Parkinsonism established for > 1 year BEFORE dementia develops --> Parkinson's Disease Dementia (PDD)

Warning

CRITICAL PRESCRIBING WARNING: EXTREME ANTIPSYCHOTIC HYPERSENSITIVITY Up to 50% of patients with DLB exhibit catastrophic, potentially lethal antipsychotic hypersensitivity when exposed to D2 dopamine receptor antagonists. Administration of first-generation antipsychotics (e.g., Haloperidol, Fluphenazine) or potent second-generation antipsychotics (e.g., Risperidone, Olanzapine) can trigger acute, severe, irreversible worsening of parkinsonian rigidity, autonomic instability, profound sedation, severe neuroleptic malignant syndrome (NMS), and sudden cardiovascular collapse or death (2- to 3-fold increased mortality).

Safe Prescribing Strategy :

Maximize non-pharmacologic calming and validation strategies; do not treat benign, non-distressing hallucinations.

Optimize Cholinesterase Inhibitors (Donepezil or Rivastigmine), which frequently reduce visual hallucinations and improve alertness by replenishing cortical acetylcholine.

If pharmacotherapy for dangerous or severely distressing psychosis is unavoidable, use lowest-dose Quetiapine (12.5 to 25 mg at bedtime) or Pimavanserin (34 mg daily) . Pimavanserin is a selective 5-HT2A inverse agonist / antagonist with ZERO dopamine D2 receptor affinity, providing antipsychotic efficacy without worsening motor parkinsonism.

Frontotemporal Lobar Degeneration (FTD / Pick Disease)

Frontotemporal dementia (FTD) represents a spectrum of non-Alzheimer dementias characterized by progressive neurodegeneration localized to the frontal and anterior temporal lobes. FTD is the leading cause of presenile dementia, with a typical age of onset between 45 and 65 years . Approximately 40% of patients report a positive family history, associated with autosomal dominant mutations in C9orf72 (hexanucleotide repeat expansion, also causing ALS), MAPT (tau), or GRN (progranulin).

Clinical Syndromic Variants

Behavioral Variant FTD (bvFTD) : The most frequent phenotype, marked by early, dramatic disintegration of personality and interpersonal conduct, while episodic memory and visuospatial orientation remain strikingly intact :

Early Disinhibition : Inappropriate sexual comments, shoplifting, public urination, reckless financial spending, or offensive jokes (Witzelsucht).

Apathy and Inertia : Loss of initiation, emotional flatness, and withdrawal from hobbies and vocational responsibilities.

Loss of Empathy / Sympathy : Complete coldness toward family members, lack of remorse, and inability to read emotional distress in others.

Hyperorality & Dietary Changes : Binging on sweets and carbohydrates, cramming excessive food into the mouth, or consuming non-food items.

Perseverative / Compulsive Behaviors : Motor stereotypies, pacing, tapping, counting, rigid daily rituals, or hoarding.

Loss of Executive Insight : Complete lack of awareness regarding the inappropriate nature of their behavior (anosodiaphoria).

Language Variants (Primary Progressive Aphasia [PPA]) :

Non-Fluent / Agrammatic Variant : Effortful, halting speech, telegraphic syntax, and sound errors, with preserved single-word comprehension.

Semantic Variant : Fluent, empty speech with profound loss of word meaning (semantic memory loss) and associative object agnosia (e.g., patient asks, "What is an apple?").

Diagnostic Hallmarks & Medication Contraindications

Neuroimaging : Brain MRI or CT shows dramatic, circumscribed frontal and anterior temporal lobar atrophy , classically producing a paper-thin, "knife-edge" appearance of the gyri with enlarged frontal horn subarachnoid spaces.

Medication Warning : Cholinesterase inhibitors (Donepezil, Rivastigmine) and Memantine are ineffective in FTD and frequently exacerbate agitation, disinhibition, and behavioral dysregulation . Pharmacotherapy relies on SSRIs (e.g., Sertraline, Citalopram) or Trazodone to modulate compulsions and irritability.

Evidence-Based Pharmacotherapy for Dementia

While current pharmacotherapies do not reverse existing neuronal destruction, disease-modifying and symptomatic medications can decelerate functional decline and stabilize cognitive performance. EVIDENCE-BASED PHARMACOTHERAPY FOR ALZHEIMER DISEASE

Drug Class & Agent Approved Stages Target Dosages & Titration Adverse Effects & Clinical Pearls

═════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════

Cholinesterase Inhibitor Mild, Moderate, Start 5 mg daily PO at bedtime; • Cholinergic: nausea, vomiting, diarrhea,

• Donepezil (Aricept) and Severe AD titrate to 10 mg daily after anorexia, weight loss, vivid dreams (shift to AM).

4 to 6 weeks. • CARDIOVASCULAR: Bradycardia, QT prolongation,

syncope, heart block; check baseline ECG!

─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

Cholinesterase Inhibitor Mild to Moderate AD Capsule: 1.5 mg BID, titrate • Higher oral GI toxicity than donepezil.

• Rivastigmine (Exelon) (Oral); Mild, Moderate, to max 6 mg BID; Transdermal • TRANSDERMAL PATCH bypasses first-pass hepatic

and Severe AD (Patch) patch: 4.6 mg/24h, titrate to metabolism, drastically reducing GI adverse

9.5 mg/24h and max 13.3 mg/24h. effects; rotate patch sites daily.

Cholinesterase Inhibitor Mild to Moderate AD IR: 4 mg BID up to 12 mg BID; • GI intolerance; caution with CYP2D6/3A4

• Galantamine (Razadyne) ER: 8 mg daily, titrate to inhibitors; avoid in severe renal/hepatic failure.

16 mg and max 24 mg daily.

NMDA Receptor Antagonist Moderate to Severe AD Start 5 mg daily PO; titrate by • Modulates glutamate excitotoxicity;

• Memantine (Namenda) (MMSE < 20 or 5 mg weekly to target dose of preserves physiologic synaptic transmission.

MoCA < 15) 10 mg BID (or 28 mg ER daily). • Well tolerated; dizziness, confusion, headache,

constipation; dose reduce in severe renal disease.

Anti-Amyloid Monoclonal Early AD (MCI due to AD Lecanemab: 10 mg/kg IV q2 weeks; • Clears amyloid-beta protofibrils and plaques.

Antibodies or Mild AD with positive Donanemab: 700 mg IV q4w x3 doses, • REQUIRES SERIAL MONITORING FOR ARIA

• Lecanemab (Leqembi) amyloid biomarkers) then 1400 mg IV q4 weeks. (ARIA-E edema, ARIA-H microhemorrhage).

• Donanemab (Kisunla) • Check APOE ε4 genotype (homozygotes high risk).

Cholinesterase Inhibitors (ChEIs)

Mechanism : Reversibly inhibit acetylcholinesterase, increasing synaptic acetylcholine availability in the neocortex and hippocampus.

Indications : Donepezil is approved across all stages (mild, moderate, severe AD). Rivastigmine patch is approved for all stages of AD and mild-to-moderate Parkinson's disease dementia.

Cardiovascular Red Flag : Increased vagal tone induces sinus bradycardia, sinoatrial block, and atrioventricular block. Any patient taking a ChEI who presents with dizziness, lightheadedness, falls, or syncope must be evaluated for medication-induced bradycardia and conduction blocks ; discontinue ChEI immediately.

NMDA Receptor Antagonist (Memantine)

Mechanism : Uncompetitive, low-affinity N-methyl-D-aspartate (NMDA) receptor antagonist. Pathologic chronic glutamate hyperactivation triggers sustained calcium influx into postsynaptic neurons, leading to excitotoxic cell death. Memantine blocks this tonic pathological noise while allowing normal physiological bursts of glutamate transmission required for learning.

Clinical Combination : Indicated for moderate-to-severe AD. When added to a cholinesterase inhibitor (e.g., Donepezil + Memantine), it provides synergistic slowing of clinical decline and behavioral stabilization compared to ChEI monotherapy.

Anti-Amyloid Monoclonal Antibodies (Lecanemab & Donanemab)

Indications : FDA-approved for confirmed Early Alzheimer Disease (Mild Cognitive Impairment due to AD or Mild Alzheimer Dementia) with documented brain amyloid pathology (positive amyloid PET scan or CSF biomarkers showing low Aβ42 and elevated phosphorylated tau).

Amyloid-Related Imaging Abnormalities (ARIA) :

ARIA-E (Edema) : Vasogenic edema and sulcal effusions resulting from increased vascular permeability during amyloid plaque clearance from cerebral blood vessel walls.

ARIA-H (Hemorrhage) : Cerebral microhemorrhages, cortical superficial siderosis, and macrohemorrhages.

Safety Protocol : Strict pre-treatment APOE genotyping is required; patients carrying two APOE ε4 alleles (homozygotes) carry an exponentially higher risk of ARIA and intracerebral hemorrhage. Serial brain MRIs are legally mandated before initiating therapy and prior to the 5th, 7th, and 14th infusions. If moderate-to-severe ARIA-E or significant ARIA-H occurs, dosing must be suspended or discontinued.

Advance Care Planning, Driving Safety & Caregiver Support
Driving Safety Assessment

Driving is a complex instrumental activity of daily living requiring divided attention, rapid visual processing, executive reaction speed, and visuospatial judgment:

Patients with moderate-to-severe dementia must not drive under any circumstances .

Patients with mild dementia or MCI warrant structured evaluation: query family regarding minor collisions, new vehicle dents, getting lost while driving familiar routes, or traffic citations.

Cognitive Benchmarks : A MoCA score <18/30 correlates strongly with driving impairment and failure on road evaluations. Formal, objective, behind-the-wheel testing through a certified driver rehabilitation specialist represents the gold standard for borderline cases.

Primary care clinicians must know their specific state reporting statutes (mandatory reporting vs. discretionary reporting with immunity).

Advance Care Planning

Discussions regarding durable power of attorney for healthcare (DPOA), living wills, financial power of attorney, and preferred goals of care (POLST/MOLST) must be initiated early in the disease course while the patient retains legal decision-making capacity .

Caregiver Burnout & Respite Care

Caregivers of individuals with dementia experience elevated rates of major depression, anxiety, physical morbidity, and premature mortality. Clinicians should routinely screen caregivers using validated instruments such as the Zarit Burden Interview (ZBI) , actively recommend local Alzheimer's Association support groups, and connect families with adult day health programs and temporary respite care.